CEL-SCI'S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer

Stock Information for Cel-Sci Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cel-Sci Corporation

CEL-SCI Appoints Mario Gobbo to Its Board of Directors
CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
CEL-SCI Corporation Issues Letter to Shareholders
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.